Genetic LRRK2 Models of Parkinson's Disease: Dissecting the Pathogenic Pathway and Exploring Clinical Applications

被引:30
作者
Yue, Zhenyu [1 ]
Lachenmayer, M. Lenard [1 ,2 ]
机构
[1] Mt Sinai Sch Med, Dept Neurol & Neurosci, New York, NY 10029 USA
[2] Univ Bonn, Dept Neurol, Bonn, Germany
关键词
Parkinson's disease; leucine-rich repeat kinase 2; genetic mouse models; G2019S; kinase inhibitors; AUTOSOMAL-DOMINANT PARKINSONISM; GENOME-WIDE ASSOCIATION; BAC TRANSGENIC MICE; KINASE-ACTIVITY; ALPHA-SYNUCLEIN; DOPAMINERGIC-NEURONS; G2019S MUTATIONS; GTP-BINDING; REPEAT; NEURODEGENERATION;
D O I
10.1002/mds.23737
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Dominantly inherited mutations in leucine-rich repeat kinase 2 are the most common cause of familial Parkinson's disease. Understanding leucine-rich repeat kinase 2 biology and pathophysiology is central to the elucidation of Parkinson's disease etiology and development of disease intervention. Recently, a number of genetic mouse models of leucine-rich repeat kinase 2 have been reported utilizing different genetic approaches. Some similarities in Parkinson's disease-related pathology emerge in these genetic models despite lack of substantial neuropathology and clinical syndromes of Parkinson's disease. The systematic characterization of these models has begun to shed light on leucine-rich repeat kinase 2 biology and pathophysiology and is expected to offer the identification and validation of drug targets. In this review, we summarize the progress of genetic leucine-rich repeat kinase 2 mouse models and discuss their utility in understanding much needed knowledge regarding early-stage (presymptomatic) disease progression, identifying drug targets, and exploring the potential to aid compound screening focused on inhibitors of kinase activity of leucine-rich repeat kinase 2. (C) 2011 Movement Disorder Society
引用
收藏
页码:1386 / 1397
页数:12
相关论文
共 71 条
  • [1] Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system
    Abeliovich, A
    Schmitz, Y
    Fariñas, I
    Choi-Lundberg, D
    Ho, WH
    Castillo, PE
    Shinsky, N
    Verdugo, JMG
    Armanini, M
    Ryan, A
    Hynes, M
    Phillips, H
    Sulzer, D
    Rosenthal, A
    [J]. NEURON, 2000, 25 (01) : 239 - 252
  • [2] PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation
    Adams, JR
    van Netten, H
    Schulzer, M
    Mak, E
    Mckenzie, J
    Strongosky, A
    Sossi, V
    Ruth, TJ
    Lee, CS
    Farrer, M
    Gasser, T
    Uitti, RJ
    Calne, DB
    Wszolek, ZK
    Stoessl, AJ
    [J]. BRAIN, 2005, 128 : 2777 - 2785
  • [3] Unexpected Lack of Hypersensitivity in LRRK2 Knock-Out Mice to MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine)
    Andres-Mateos, Eva
    Mejias, Rebeca
    Sasaki, Masayuki
    Li, Xiaojie
    Lin, Brian M.
    Biskup, Saskia
    Zhang, Li
    Banerjee, Rebecca
    Thomas, Bobby
    Yang, Lichuan
    Liu, Guosheng
    Beal, M. Flint
    Huso, David L.
    Dawson, Ted M.
    Dawson, Valina L.
    [J]. JOURNAL OF NEUROSCIENCE, 2009, 29 (50) : 15846 - 15850
  • [4] Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
    Barrett, Jeffrey C.
    Hansoul, Sarah
    Nicolae, Dan L.
    Cho, Judy H.
    Duerr, Richard H.
    Rioux, John D.
    Brant, Steven R.
    Silverberg, Mark S.
    Taylor, Kent D.
    Barmada, M. Michael
    Bitton, Alain
    Dassopoulos, Themistocles
    Datta, Lisa Wu
    Green, Todd
    Griffiths, Anne M.
    Kistner, Emily O.
    Murtha, Michael T.
    Regueiro, Miguel D.
    Rotter, Jerome I.
    Schumm, L. Philip
    Steinhart, A. Hillary
    Targan, Stephan R.
    Xavier, Ramnik J.
    Libioulle, Cecile
    Sandor, Cynthia
    Lathrop, Mark
    Belaiche, Jacques
    Dewit, Olivier
    Gut, Ivo
    Heath, Simon
    Laukens, Debby
    Mni, Myriam
    Rutgeerts, Paul
    Van Gossum, Andre
    Zelenika, Diana
    Franchimont, Denis
    Hugot, Jean-Pierre
    de Vos, Martine
    Vermeire, Severine
    Louis, Edouard
    Cardon, Lon R.
    Anderson, Carl A.
    Drummond, Hazel
    Nimmo, Elaine
    Ahmad, Tariq
    Prescott, Natalie J.
    Onnie, Clive M.
    Fisher, Sheila A.
    Marchini, Jonathan
    Ghori, Jilur
    [J]. NATURE GENETICS, 2008, 40 (08) : 955 - 962
  • [5] Localization of LRRK2 to membranous and vesicular structures in mammalian brain
    Biskup, Saskia
    Moore, Darren J.
    Celsi, Fulvio
    Higashi, Shinji
    West, Andrew B.
    Andrabi, Shaida A.
    Kurkinen, Kaisa
    Yu, Seong-Woon
    Savitt, Joseph M.
    Waldvogel, Henry J.
    Faull, Richard L. M.
    Emson, Piers C.
    Torp, Reldun
    Ottersen, Ole P.
    Dawson, Ted M.
    Dawson, Valina L.
    [J]. ANNALS OF NEUROLOGY, 2006, 60 (05) : 557 - 569
  • [6] CHENG F, 2010, J CHEM NEUROANAT
  • [7] Frequency of LRRK2 mutations in early- and late-onset Parkinson disease
    Clark, L. N.
    Wang, Y.
    Karlins, E.
    Saito, L.
    Mejia-Santana, H.
    Harris, J.
    Louis, E. D.
    Cote, L. J.
    Andrews, H.
    Fahn, S.
    Waters, C.
    Ford, B.
    Frucht, S.
    Ottman, R.
    Marder, K.
    [J]. NEUROLOGY, 2006, 67 (10) : 1786 - 1791
  • [8] The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
    Cookson, Mark R.
    [J]. NATURE REVIEWS NEUROSCIENCE, 2010, 11 (12) : 791 - 797
  • [9] A comparative study of Lrrk2 function in primary neuronal cultures
    Daechsel, Justus C.
    Behrouz, Bahareh
    Yue, Mei
    Beevers, Joel E.
    Melrose, Heather L.
    Farrer, Matthew J.
    [J]. PARKINSONISM & RELATED DISORDERS, 2010, 16 (10) : 650 - 655
  • [10] Genetic Animal Models of Parkinson's Disease
    Dawson, Ted M.
    Ko, Han Seok
    Dawson, Valina L.
    [J]. NEURON, 2010, 66 (05) : 646 - 661